Chaazzle is right in his assertions...EACH indication will have a different reaction chemically...each patient/group will have a different reaction to the MOA of LL...I am sure that as these trials unfold with news ...we'll have a better understanding of effective dosages etc. per the patient population...The one thing I am sure of...is that the management starting with CA and strengthening through the SAB...will ensure our @$$ is protected...because ultimately it's their @$$ as well...again, both financially and legally.